Using organoids to predict treatment outcomes in head and neck cancer
SOTO Study: Prospective Study to Correlate the Treatment Sensitivity of Patient-derived Organoids With Clinical Outcomes in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients
Guy's and St Thomas' NHS Foundation Trust · NCT05400239
This study is testing if lab-grown mini tumors from head and neck cancer patients can help predict how well different treatments will work for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Guy's and St Thomas' NHS Foundation Trust (other) |
| Locations | 1 site (London) |
| Trial ID | NCT05400239 on ClinicalTrials.gov |
What this trial studies
This observational study aims to generate patient-derived organoids (PDOs) from samples of patients with head and neck squamous cell carcinoma (HNSCC). The study will assess the sensitivity of these organoids to various treatments and correlate their responses with the actual treatment outcomes experienced by the patients. By analyzing the radiosensitivity and chemosensitivity of the PDOs, researchers hope to gather preliminary data that could help predict patient survival outcomes based on their organoid responses.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with head and neck squamous cell carcinoma who are undergoing curative treatment.
Not a fit: Patients who are unable to provide informed consent due to mental disabilities or other vulnerabilities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment plans for patients with head and neck cancer, improving their chances of survival.
How similar studies have performed: While the use of organoids in predicting treatment responses is a growing field, this specific approach in HNSCC is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with head and neck squamous cell carcinoma (including oral cavity, oropharynx, paranasal sinuses, hypopharynx or larynx) undergoing curative treatment (primary surgery or radiotherapy) or presenting with recurrent or metastatic cancers * Age \> 18 years old Exclusion Criteria: * Patients unable to give informed consent e.g. mental disability or vulnerable adults
Where this trial is running
London
- Guys Hospital — London, United Kingdom (RECRUITING)
Study contacts
- Study coordinator: Anthony Kong
- Email: anthony.kong@kcl.ac.uk
- Phone: 0207-848-8302
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer